Drugs / IMM2520
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05780307 | Mar 2023 → Mar 2024 | breast cancer, colorectal cancer, head and neck squamous cell carcinoma, non-small cell lung carcinoma +1 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-10-28 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Results 宜明昂科IMM2520临床前研究数据在《Heliyon》期刊上发表 immuneonco.com ↗
2024年10月28日，宜明昂科生物医药技术(上海)股份有限公司(简称“宜明昂科”，香港交易所股票代码：01541.HK)研究团队，将IMM2520 临床前研究数据 “ IMM2520, a novel anti-CD47/PD-L1 bispecific antibody for cancer immune therapy ” 为题发表在《Heliyon》期刊。 |
| 2024-09-18 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Results 2024 ESMO丨宜明昂科替达派西普(IMM01) 两项口头报告等临床研究成果引起热烈反响 immuneonco.com ↗
在所有评估剂量下，IMM2520耐受性良好，并在晚期实体瘤中显示出初步的抗肿瘤活性，特别是在SCLC患者中： |
| 2022-12-14 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Regulatory 宜明昂科IMM2520项目获得美国FDA临床试验研究许可 immuneonco.com ↗
2022年12月14日，宜明昂科生物医药技术(上海)股份有限公司（以下简称“宜明昂科”）宣布，公司自主研发的、同时靶向CD47和PD-L1的双特异性抗体-受体重组蛋白药物(项目编号:IMM2520）获得美国FDA临床试验研究许可。 |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-10-28 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 宜明昂科IMM2520临床前研究数据在《Heliyon》期刊上发表 immuneonco.com ↗ |
| 2024-09-18 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2024 ESMO丨宜明昂科替达派西普(IMM01) 两项口头报告等临床研究成果引起热烈反响 immuneonco.com ↗ |
| 2023-03-24 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 宜明昂科IMM47、IMM2520、IMM2510发明专利获得中国国家知识产权局授权 immuneonco.com ↗ |
| 2022-12-14 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 宜明昂科IMM2520项目获得美国FDA临床试验研究许可 immuneonco.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMM2520 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05780307 ↗ |
| Modality | Monoclonal antibody | “IMM2520 is a recombinant bispecific monoclonal antibody with high affinity to the dual targets, PD-L1 and CD47” NCT05780307 ↗ |
| Route | Intravenous | “administered once a week intravenously” NCT05780307 ↗ |